Phase I/II study of novel oral fluoropyrimidine S-1 in combination with oxaliplatin (SOX) as first-line chemotherapy for metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Tahara, M. [1 ]
Yamada, Y. [2 ]
Ohtsu, A. [1 ]
Shirao, K. [2 ]
Shimada, Y. [2 ]
Sasaki, Y. [3 ]
Yamamoto, W. [3 ]
Satoh, T. [4 ]
Okamoto, W. [4 ]
Tanigawara, Y. [5 ]
机构：
[1] Natl Canc Ctr Hosp E, Div Endoscopy & GI Oncol, Kashiwa, Chiba, Japan
[2] Natl Canc Ctr, Gastrointestinal Oncol Div, Tokyo, Japan
[3] Saitama Med Univ Int, Med Ctr, Dept Clin Oncol, Saitama, Japan
[4] Kinki Univ, Sch Med, Dept Med Oncol, Osaka, Japan
[5] Keio Univ Hosp, Dept Pharm, Tokyo, Japan
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)70989-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3061
引用
收藏
页码：254 / 254
页数：1
相关论文
共 50 条
  • [21] A phase II study of S-1 and oxaliplatin as first-line therapy for patients with recurrent or metastatic gastric cancer
    Kim, H.
    Lee, G.
    Kim, H.
    Lee, O.
    Hwang, I.
    Kang, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [22] Microsatellite instability and sensitivity to fluoropyrimidine and oxaliplatin containing first-line chemotherapy in metastatic colorectal cancer
    Liu, Jia
    Wang, Biao
    Fang, Wentong
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2020, 27 (05) : 267 - 270
  • [23] Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma
    Ohtsu, A
    Baba, H
    Sakata, Y
    Mitachi, Y
    Horikoshi, N
    Sugimachi, K
    Taguchi, T
    BRITISH JOURNAL OF CANCER, 2000, 83 (02) : 141 - 145
  • [24] Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma
    Ohtsu A.
    Baba H.
    Sakata Y.
    Mitachi Y.
    Horikoshi N.
    Sugimachi K.
    Taguchi T.
    British Journal of Cancer, 2000, 83 (2) : 141 - 145
  • [25] PHASE II STUDY OF COMBINATION CHEMOTHERAPY WITH ORAL S-1 AND OXALIPLATIN (SOX) IN PATIENTS WITH MUCINOUS ADENOCARCINOMA OF THE OVARY
    Nishio, S.
    Shimada, M.
    Kamura, T.
    Ishitani, K.
    Ochiai, K.
    Takeshima, N.
    Yokoyama, Y.
    Furumoto, H.
    Sugiyama, T.
    Kigawa, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 326 - 326
  • [26] Phase I study of oral fluoropyrimidine S-1 plus oral leucovorin in patients with metastatic colorectal cancer
    Hyodo, Ichinosuke
    Nishina, Tomohiro
    Boku, Narikazu
    Yoshino, Takayuki
    Narahara, Hiroyuki
    Sugimoto, Naotoshi
    ANNALS OF ONCOLOGY, 2006, 17 : 120 - 121
  • [27] A phase I pharmacokinetic (PK) study of TSU-68 plus S-1 and oxaliplatin (SOX) in patients with metastatic colorectal cancer (mCRC) treated with prior chemotherapy
    Shin, Sang Joon
    Ahn, Joong Bae
    Jeung, Hei-Cheul
    Rha, Sun Young
    Roh, Jae Kyung
    Ahn, Jung Ryun
    Kim, Chan
    Chung, Hyun Cheol
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [28] Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer
    Yamada, Yasuhide
    Yamaguchi, Tatsuro
    Matsumoto, Hiroshi
    Ichikawa, Yasushi
    Goto, Ayumu
    Kato, Ken
    Hamaguchi, Tetsuya
    Shimada, Yasuhiro
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) : 1690 - 1696
  • [29] Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer
    Yasuhide Yamada
    Tatsuro Yamaguchi
    Hiroshi Matsumoto
    Yasushi Ichikawa
    Ayumu Goto
    Ken Kato
    Tetsuya Hamaguchi
    Yasuhiro Shimada
    Investigational New Drugs, 2012, 30 : 1690 - 1696
  • [30] Phase II study of oxaliplatin combined with S-1 (SOX) as first-line therapy for patients with advanced gastric cancer (AGC)
    Takiuchi, H.
    Koizumi, W.
    Yamada, Y.
    Boku, N.
    Komatsu, Y.
    Fuse, N.
    Muro, K.
    Tsuburaya, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345